Compare VanEck Semiconductor ETF (SMH) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs Viatris Inc — how do they compare? VanEck Semiconductor ETF trades at $603.37 (market cap $73.92B), while Viatris Inc trades at $17.63 (market cap $20.03B). The key difference: VanEck Semiconductor ETF is far larger — about 3.7× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Semiconductor ETF for 101 Days and Viatris Inc for 57 Days on average.
| SMH | VTRS | |
|---|---|---|
Market Cap | $73.92B | $20.03B |
Volume | 11,050,892 | 14,109,977 |
52-Week High | $668.91 | $18.27 |
52-Week Low | $325.10 | $9.74 |
Typical Hold Time | 101 Days | 57 Days |
Sector | — | Health |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH (VanEck Semiconductor ETF) trades at $606.11, down 3.03% on the day, but maintains a strong bullish technical outlook with moving averages signaling continued strength. The ETF has delivered exceptional 69% returns year-to-date through September 30, 2026, significantly outperforming major semiconductor holdings like Nvidia. Recent sector momentum is supported by positive industry developments including AMD's $8.2 billion acquisition of World Labs and Bank of America's projection that the global chip market will nearly double by 2030.
The semiconductor sector's structural growth drivers, particularly in AI hardware, support continued ETF appreciation, though concentration risk in top holdings and elevated RSI levels near 76 suggest potential near-term consolidation. Investors benefit from diversified exposure to the physical AI infrastructure boom, but should monitor valuation metrics as the sector trades at elevated levels following substantial gains.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
